Search

Your search keyword '"Richly, Heike"' showing total 139 results
Start Over Author "Richly, Heike"
139 results on '"Richly, Heike"'

1. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Author

Melero, Ignacio, de Miguel Luken, Maria, de Velasco, Guillermo, Garralda, Elena, Martín-Liberal, Juan, Joerger, Markus, Alonso, Guzman, Goebeler, Maria-Elisabeth, Schuler, Martin, König, David, Dummer, Reinhard, Reig, Maria, Rodriguez Ruiz, Maria-Esperanza, Calvo, Emiliano, Esteban-Villarrubia, Jorge, Oberoi, Arjun, Sabat, Paula, Soto-Castillo, Juan José, Koster, Kira-Lee, Saavedra, Omar, Sayehli, Cyrus, Gromke, Tanja, Läubli, Heinz, Ramelyte, Egle, Fortuny, Marta, Landa-Magdalena, Ana, Moreno, Irene, Torres-Jiménez, Javier, Hernando-Calvo, Alberto, Hess, Dagmar, Racca, Fabricio, Richly, Heike, Schmitt, Andreas M., Eggenschwiler, Corinne, Sanduzzi-Zamparelli, Marco, Vilalta-Lacarra, Anna, Trojan, Jörg, Koch, Christine, Galle, Peter R., Foerster, Friedrich, Trajanoski, Zlatko, Hackl, Hubert, Gogolla, Falk, Koll, Florestan J., Wild, Peter, Chun, Felix Kyoung Hwan, Reis, Henning, Lloyd, Peter, Machacek, Matthias, Gajewski, Thomas F., Fridman, Wolf H., Eggermont, Alexander M. M., Bargou, Ralf, Schöniger, Sandra, Rüschoff, Josef, Tereshchenko, Anastasiia, Zink, Carina, da Silva, Antonio, Lichtenegger, Felix S., Akdemir, Julia, Rüdiger, Manfred, L’Huillier, Phil, Dutta, Aradhana, Haake, Markus, Auckenthaler, Alexandra, Gjorgjioska, Ana, Rössler, Bernhard, Hermann, Frank, Liebig, Mara, Reichhardt, Daniela, Schuberth-Wagner, Christine, Wischhusen, Jörg, Fettes, Petra, Auer, Marlene, Klar, Kathrin, and Leo, Eugen

Published
2024
Full Text
View/download PDF

2. Liver volumetry improves evaluation of treatment response to hepatic artery infusion chemotherapy in uveal melanoma patients with liver metastases

Author

Zensen Sebastian, Steinberg-Vorhoff Hannah L, Milosevic Aleksandar, Richly Heike, Siveke Jens T, Opitz Marcel, Haubold Johannes, Li Yan, Forsting Michael, and Schaarschmidt Benedikt Michael

Subjects
uveal melanoma, computed tomography, liver volumetry, staging, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

In uveal melanoma patients, short-term evaluation of treatment response to hepatic artery infusion chemotherapy (HAIC) using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria is challenging due to the diffuse metastatic spread. As liver enlargement can frequently be observed, this study aims to compare RECIST 1.1 and liver volumetry (LV) for the evaluation of HAIC treatment response.

Published
2024
Full Text
View/download PDF

4. Prognostic value of clinical and radiomic parameters in patients with liver metastases from uveal melanoma.

Author

Lever, Mael, Bogner, Simon, Giousmas, Melina, Mairinger, Fabian D., Baba, Hideo A., Richly, Heike, Gromke, Tanja, Schuler, Martin, Bechrakis, Nikolaos E., and Kalkavan, Halime

Subjects
PATIENT experience, PROGNOSIS, OVERALL survival, SURVIVAL rate, PATIENTS' attitudes
Abstract

Approximately every second patient with uveal melanoma develops distant metastases, with the liver as the predominant target organ. While the median survival after diagnosis of distant metastases is limited to a year, yet‐to‐be‐defined subgroups of patients experience a more favorable outcome. Therefore, prognostic biomarkers could help identify distinct risk groups to guide patient counseling, therapeutic decision‐making, and stratification of study populations. To this end, we retrospectively analyzed a cohort of 101 patients with newly diagnosed hepatic metastases from uveal melanoma by using Cox‐Lasso regression machine learning, adapted to a high‐dimensional input parameter space. We show that substantial binary risk stratification can be performed, based on (i) clinical and laboratory parameters, (ii) measures of quantitative overall hepatic tumor burden, and (iii) radiomic parameters. Yet, combining two or all three domains failed to improve prognostic separation of patients. Additionally, we identified highly relevant clinical parameters (including lactate dehydrogenase, thrombocyte counts, aspartate transaminase, and the metastasis‐free interval) at first diagnosis of metastatic disease as predictors for time‐to‐treatment failure and overall survival. Taken together, the risk stratification models, built by our machine‐learning algorithm, identified a comparable and independent prognostic value of clinical, radiological, and radiomic parameters in uveal melanoma patients with hepatic metastases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion

Author

Ludwig Johannes M., Haubold Johannes, Bauer Sebastian, Richly Heike, Siveke Jens T., Wimmer Julia, Umutlu Lale, Schaarschmidt Benedikt M., and Theysohn Jens M.

Subjects
uveal melanoma, liver metastases, transarterial hepatic chemoperfusion, melphalan, inflammatory markers, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

The aim of the study was to evaluate pretreatment inflammatory markers as prognostic factors in patients with unresectable uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion.

Published
2021
Full Text
View/download PDF

6. Are histomorphological patterns a predictor for survival in uveal melanoma patients with hepatic metastases undergoing hepatic artery infusion chemotherapy?

Author

Steinberg‐Vorhoff, Hannah L, Ting, Saskia C, Zensen, Sebastian, Ludwig, Johannes M, Li, Yan, Richly, Heike, Grüneisen, Johannes, Siveke, Jens T, Theysohn, Jens M, and Schaarschmidt, Benedikt M

Subjects
HEPATIC artery, INFUSION therapy, CELL aggregation, PALLIATIVE treatment, OVERALL survival
Abstract

Introduction: In uveal melanoma (UM) patients with hepatic metastases, hepatic artery infusion chemotherapy (HAIC) is a viable, palliative treatment option. To evaluate the impact of two histomorphological patterns (spindle cell vs. epithelioid) of liver metastases on median overall survival (mOS) in UM patients undergoing HAIC. Methods: A retrospective analysis with 60 UM patients (29 females, mean age: 61.6 ± 12.1 years) with hepatic metastases was performed. Histomorphological patterns in metastases were analysed and classified as either predominant spindle cell or epithelioid pattern. mOS between both patient groups was analysed using Kaplan–Meier curves and the log‐rank test. Results: In 73.3% (44/60) of the metastases, a predominant epithelioid pattern, in 21.7% (13/60) a predominant spindle cell pattern, and in 5% (3/60) other patterns were found. No significant differences between patients with an epithelioid (mOS: 14.2 months, 95% CI: 8.8–19.6) and a spindle cell pattern (mOS: 14.4 months, 95% CI: 4.3–24.5) were detected by the log‐rank test, χ2(2) = 0.22, P = 0.881. Conclusion: Histomorphological patterns of UM metastases do not seem to be a predictor for mOS in UM patients undergoing HAIC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

Author

Schuler, Martin, Cho, Byoung Chul, Sayehli, Cyrus Michael, Navarro, Alejandro, Soo, Ross A, Richly, Heike, Cassier, Philippe Alexandre, Tai, David, Penel, Nicolas, Nogova, Lucia, Park, Se Hoon, Schostak, Martin, Gajate, Pablo, Cathomas, Richard, Rajagopalan, Prabhu, Grevel, Joachim, Bender, Sebastian, Boix, Oliver, Nogai, Hendrik, Ocker, Matthias, Ellinghaus, Peter, and Joerger, Markus

Published
2019
Full Text
View/download PDF

10. Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study

Author

Tomsitz, Dirk, primary, Ruf, Theresa, additional, Heppt, Markus, additional, Staeger, Ramon, additional, Ramelyte, Egle, additional, Dummer, Reinhard, additional, Garzarolli, Marlene, additional, Meier, Friedegund, additional, Meier, Eileen, additional, Richly, Heike, additional, Gromke, Tanja, additional, Siveke, Jens T., additional, Franklin, Cindy, additional, Klespe, Kai-Christian, additional, Mauch, Cornelia, additional, Kilian, Teresa, additional, Seegräber, Marlene, additional, Schilling, Bastian, additional, French, Lars E., additional, Berking, Carola, additional, and Heinzerling, Lucie, additional

Published
2023
Full Text
View/download PDF

11. Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study

Author

Tomsitz, Dirk; https://orcid.org/0000-0003-0036-072X, Ruf, Theresa, Heppt, Markus; https://orcid.org/0000-0003-4603-1825, Staeger, Ramon; https://orcid.org/0000-0002-9283-9596, Ramelyte, Egle; https://orcid.org/0000-0001-8262-8608, Dummer, Reinhard; https://orcid.org/0000-0002-2279-6906, Garzarolli, Marlene, Meier, Friedegund, Meier, Eileen, Richly, Heike, Gromke, Tanja, Siveke, Jens T; https://orcid.org/0000-0002-8772-4778, Franklin, Cindy; https://orcid.org/0000-0001-9142-5423, Klespe, Kai-Christian, Mauch, Cornelia, Kilian, Teresa, Seegräber, Marlene, Schilling, Bastian; https://orcid.org/0000-0001-8859-4103, French, Lars E; https://orcid.org/0000-0002-4629-1486, Berking, Carola; https://orcid.org/0000-0003-0229-8931, Heinzerling, Lucie, Tomsitz, Dirk; https://orcid.org/0000-0003-0036-072X, Ruf, Theresa, Heppt, Markus; https://orcid.org/0000-0003-4603-1825, Staeger, Ramon; https://orcid.org/0000-0002-9283-9596, Ramelyte, Egle; https://orcid.org/0000-0001-8262-8608, Dummer, Reinhard; https://orcid.org/0000-0002-2279-6906, Garzarolli, Marlene, Meier, Friedegund, Meier, Eileen, Richly, Heike, Gromke, Tanja, Siveke, Jens T; https://orcid.org/0000-0002-8772-4778, Franklin, Cindy; https://orcid.org/0000-0001-9142-5423, Klespe, Kai-Christian, Mauch, Cornelia, Kilian, Teresa, Seegräber, Marlene, Schilling, Bastian; https://orcid.org/0000-0001-8859-4103, French, Lars E; https://orcid.org/0000-0002-4629-1486, Berking, Carola; https://orcid.org/0000-0003-0229-8931, and Heinzerling, Lucie

Abstract

Background: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting. Patients and Methods: This retrospective, multicenter study analyzed the outcomes and safety of tebentafusp therapy in 78 patients with mUM. Results: Patients treated with tebentafusp had a median PFS of 3 months (95% CI 2.7 to 3.3) and a median OS of 22 months (95% CI 10.6 to 33.4). In contrast to a published Phase 3 study, our cohort had a higher rate of patients with elevated LDH (65.4% vs. 35.7%) and included patients with prior systemic and local ablative therapies. In patients treated with tebentafusp following ICI, there was a trend for a longer median OS (28 months, 95% CI 26.9 to 29.1) compared to the inverse treatment sequence (24 months, 95% CI 13.0 to 35.0, p = 0.257). The most common treatment-related adverse events were cytokine release syndrome in 71.2% and skin toxicity in 53.8% of patients. Tumor lysis syndrome occurred in one patient. Conclusions: Data from this real-life cohort showed a median PFS/OS similar to published Phase 3 trial data. Treatment with ICI followed by tebentafusp may result in longer PFS/OS compared to the inverse treatment sequence.

Published
2023

14. Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center

Author

Wiesweg, Marcel, Ting, Saskia, Reis, Henning, Worm, Karl, Kasper, Stefan, Tewes, Mitra, Welt, Anja, Richly, Heike, Meiler, Johannes, Bauer, Sebastian, Hense, Jörg, Gauler, Thomas C., Köhler, Jens, Eberhardt, Wilfried E., Darwiche, Kaid, Freitag, Lutz, Stamatis, Georgios, Breitenbücher, Frank, Wohlschlaeger, Jeremias, Theegarten, Dirk, Derks, Cordula, Cortes-Incio, Diana, Linden, Gabriele, Skottky, Silke, Lütkes, Peter, Dechêne, Alexander, Paul, Andreas, Markus, Peter, Schmid, Kurt W., and Schuler, Martin

Published
2013
Full Text
View/download PDF

15. Abstract P06-01: A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

Author

Melero, Ignacio, primary, Calvo, Emiliano, additional, Goebeler, Maria-Elisabeth, additional, Garralda, Elena, additional, Dummer, Reinhard, additional, Rodríguez-Ruiz, María, additional, De Miguel, María, additional, Sayehli, Cyrus, additional, Casal, Guzman Alonso, additional, Ramelyte, Egle, additional, Schuler, Martin, additional, Gromke, Tanja, additional, Sanmamed, Miguel, additional, Moreno, Irene, additional, Bargou, Ralf, additional, Lostes, Maria, additional, Maul, Julia-Tatjana, additional, Richly, Heike, additional, Fettes, Petra, additional, Klar, Kathrin, additional, Schuberth-Wagner, Christine, additional, Haake, Markus, additional, Wischhusen, Joerg, additional, and Leo, Eugen, additional

Published
2021
Full Text
View/download PDF

16. 504 A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

Author

Melero, Ignacio, primary, Calvo, Emiliano, additional, Goebeler, Maria-Elisabeth, additional, Garralda, Elena, additional, Dummer, Reinhard, additional, Rodríguez-Ruiz, María, additional, Miguel, Maria de, additional, Sayehli, Cyrus Michael, additional, Casal, Guzman Alonso, additional, Ramelyte, Egle, additional, Schuler, Martin, additional, Gromke, Tanja, additional, Sanmamed, Miguel, additional, Moreno, Irene, additional, Bargou, Ralf, additional, Lostes, Maria, additional, Maul, Julia-Tatjana, additional, Eggenschwiler, Corinne, additional, Richly, Heike, additional, Fettes, Petra, additional, Klar, Kathrin, additional, Schuberth-Wagner, Christine, additional, Haake, Markus, additional, Wischhusen, Jörg, additional, and Leo, Eugen, additional

Published
2021
Full Text
View/download PDF

17. Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion

Author

Ludwig, Johannes M., Haubold, Johannes, Bauer, Sebastian, Richly, Heike, Siveke, Jens, Wimmer, Julia, Umutlu, Lale, Schaarschmidt, Benedikt M., and Theysohn, Jens

Subjects
Adult, Blood Platelets, Male, Uveal Neoplasms, Medizinische Fakultät » Universitätsklinikum Essen » Innere Klinik (Tumorforschung), Neutrophils, Medizin, R895-920, Antineoplastic Agents, Kaplan-Meier Estimate, Nitrosourea Compounds, Medizinische Fakultät » Universitätsklinikum Essen » Westdeutsches Tumorzentrum Essen (WTZ), Medical physics. Medical radiology. Nuclear medicine, Organophosphorus Compounds, Biomarkers, Tumor, Humans, Aspartate Aminotransferases, Lymphocytes, ddc:610, Melanoma, Melphalan, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, transarterial hepatic chemoperfusion, Liver Neoplasms, Alanine Transaminase, Middle Aged, Prognosis, inflammatory markers, eye diseases, Tumor Burden, melphalan, C-Reactive Protein, Medizinische Fakultät » Universitätsklinikum Essen » Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie, Chemotherapy, Cancer, Regional Perfusion, Female, uveal melanoma, liver metastases, Research Article
Abstract

Background The aim of the study was to evaluate pretreatment inflammatory markers as prognostic factors in patients with unresectable uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion. Patients and methods 54 patients (44% male, median age: 61 years) were retrospectively assessed. A median of 3 (range: 1–11) treatment sessions were performed with melphalan (92%) or fotemustin (8%). Inflammatory indices were calculated as follows: neutrophils/nl to lymphocytes/nl ratio (NLR), systemic immune-inflammation index ([platelets/nl × neutrophils/nl]/[lymphocytes/nl]; SII), and platelets/nl to lymphocytes/nl ratio (PLR). The cut-off for dichotomization purposes was set at the median (inflammatory indices, hepatic tumor burden) or the upper level of normal. Kaplan Meier analysis was performed for median overall survival (OS) in months, and Cox proportional hazard model for uni(UVA) and multivariate (MVA) hazard ratio (HR, 95%CI) analyses were performed. Results Median OS of the study cohort was 7.7 (6.3–10.9) months. In UVA OS was prolonged for low C reactive protein (CRP) (13.5 vs. 5.2; p = 0.0005), low SII (10.8 vs. 5.6; p = 0.0005), low NLR (11.1 vs. 6.3; p = 0.0045), low aspartate aminotransferase (AST) (11.5 vs. 5.6; p = 0.015), alanine aminotransferases (ALT) (11.5 vs. 5.6; p = 0.01), and tumor burden ≦ 50% (8.2 vs. 4.8; p = 0.007). MVA confirmed low CRP (HR: 0.29, 0.11–0.7; p = 0.005), low SII (HR: 0.19, 0.11–0.7; p = 0.008), and low ALT (HR: 0.13, 0.02–0.63; p = 0.011) as independent predictors for prolonged OS. Patients with ≦ 1, 2, 3 elevated significant MVA-factors survived a median of 14.9, 7.7, and 3.9 months, respectively (p = 0.0001). Conclusions Pretreatment inflammatory markers (CRP, SII) and AST were independent prognostic survival markers in patients with uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion. A combination of factors may help to identify patients potentially benefitting from treatment.

Published
2021

18. Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients

Author

Welt, Anja, Tewes, Mitra, Aktas, Bahriye, Hoffmann, Oliver, Wiesweg, Marcel, Ting, Saskia, Reis, Henning, Worm, Karl, Richly, Heike, Hense, Jörg, Palmer, Michael R., Lee, Benjamin H., Wendling, Johanna, Kossow, Josef, Scheulen, Max E., Lehnerdt, Cathrin, Kohl, Marzena, Derks, Cordula, Skottky, Silke, Haus, Ulrike, Schmid, Kurt W., Kimmig, Rainer, Schuler, Martin, and Kasper, Stefan

Published
2013
Full Text
View/download PDF

21. A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

Author

Melero, Ignacio, Calvo, Emiliano, Goebeler, Maria-Elisabeth, Garralda, Elena, Dummer, Reinhard, Rodríguez-Ruiz, María, Miguel, Maria de, Sayehli, Cyrus Michael, Casal, Guzman Alonso, Ramelyte, Egle, Schuler, Martin, Gromke, Tanja, Sanmamed, Miguel, Moreno, Irene, Bargou, Ralf, Lostes, Maria, Maul, Julia-Tatjana, Eggenschwiler, Corinne, Richly, Heike, Fettes, Petra, Klar, Kathrin, Schuberth-Wagner, Christine, Haake, Markus, Wischhusen, Jörg, and Leo, Eugen

Subjects
Medizin
Published
2021

28. Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway

Author

Schuler, Martin, Cassier, P., Penel, N., Cathomas, R., Richly, Heike, Schostak, M., Janitzky, A., Wermke, M., Nogova, L., Tai, D., Sayehli, C., Grüllich, C., Grande, E., Navarro, A., Park, S. H., Nogai, H., Bender, S., Ellinghaus, P., and Joerger, M.

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2018

29. Konjunktivales Melanom : Standardisiertes Vorgehen in Diagnostik, Therapie und Nachsorge

Author

Glossmann, Jan‑Peter, Skoetz, Nicole, Starbatty, Barbara, Bischoff, Martina, Leyvraz, Serge, Westekemper, Henrike, Materna, Verena, Troost, Esther, Noak, Karina, Benito Rabenort, Michael, Palm, Stefan, Kemink, Timm, Degener, Kristina, Reimer, Carola, Schafhausen, Philippe, Dietrich, Mareike, Hale, Katrin, Scheid, Christof, Schneider, Victoria, Pretzell, Elke Ina, Dorn, Julia, Böck, Stefan, Kraus-Pfeiffer, Gabriele, Seckinger, Andrea, Sommer, Rebekka, Schauer, Ute, Krein, Axel, Meier, Friedegund, Sommer, Falk, Kreis, Stefan, Richly, Heike, Bauer, Sebastian, Griewank, Klaus, Hrgovic, Igor, Meissner, Markus, Wolff, Robert, Auw-Hädrich, Claudia, Reinhard, Thomas, von Bubnoff, Dagmar, Fuisting, Bettina, Staub, Janina, Hassel, Jessica C., Marnitz-Schulze, Karolina Simone, Schlaak, Max, Laspas, Panagiotis, Loquai, Carmen, Siedlecki, Jakob, Süsskind, Daniela, Paulsen, Frank, Eigentler, Thomas, Treiber, Nikolai, Ach, Thomas, Gesierich, Anja, Kampik, Daniel, and Heindl, Ludwig M.

Subjects
medicine.medical_specialty, animal structures, business.industry, General surgery, Melanoma, media_common.quotation_subject, Operating procedures, Medizin, Cancer, medicine.disease, Rare cancer, Follow up care, 03 medical and health sciences, Ophthalmology, 0302 clinical medicine, Diagnosis treatment, Excellence, 030221 ophthalmology & optometry, medicine, 030211 gastroenterology & hepatology, business, Conjunctival Melanoma, media_common
Abstract

BACKGROUND In cases of rare cancer entities, such as malignant melanoma of the conjunctiva, there are often no evidence-based national guidelines available. Standard operating procedures (SOP) are an alternative in these cases. OBJECTIVE The aim of this project was to develop a consensus SOP for diagnosis, treatment, and follow-up care of conjunctival melanomas between the 14 Centers of Excellence in Germany supported by German Cancer Aid. METHODS The SOP was prepared according to a defined process including timelines, flow of information, and roles. RESULTS AND CONCLUSION This is the first consensus SOP of the Centers of Excellence in Germany (certified by the German Cancer Aid) regarding diagnosis, treatment, and follow-up for malignant melanomas of the conjunctiva.

Published
2018

30. Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.

Author

Joerger, Markus, primary, Cassier, Philippe Alexandre, additional, Penel, Nicolas, additional, Cathomas, Richard, additional, Richly, Heike, additional, Schostak, Martin, additional, Janitzky, Andreas, additional, Wermke, Martin, additional, Nogova, Lucia, additional, Tai, David Wai-Meng, additional, Sayehli, Cyrus, additional, Grüllich, Carsten, additional, Grande, Enrique, additional, Navarro, Alejandro, additional, Park, Se Hoon, additional, Nogai, Hendrik, additional, Bender, Sebastian, additional, Ellinghaus, Peter, additional, and Schuler, Martin H., additional

Published
2018
Full Text
View/download PDF

31. Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.

Author

Joerger, Markus, primary, Cassier, Philippe, additional, Penel, Nicolas, additional, Cathomas, Richard, additional, Richly, Heike, additional, Schostak, Martin, additional, Janitzky, Andreas, additional, Wermke, Martin, additional, Nogova, Lucia, additional, Tai, David Wai-Meng, additional, Sayehli, Cyrus, additional, Grüllich, Carsten, additional, Grande, Enrique, additional, Navarro, Alejandra, additional, Park, Se Hoon, additional, Gillessen, Silke, additional, Nogai, Hendrik, additional, Bender, Sebastian, additional, Ellinghaus, Peter, additional, and Schuler, Martin H., additional

Published
2018
Full Text
View/download PDF

32. Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.

Author

Joerger, Markus, Cassier, Philippe, Penel, Nicolas, Cathomas, Richard, Richly, Heike, Schostak, Martin, Janitzky, Andreas, Wermke, Martin, Nogova, Lucia, Tai, David Wai-Meng, Sayehli, Cyrus, Gruellich, Carsten, Grande, Enrique, Navarro, Alejandra, Park, Se Hoon, Gillessen, Silke, Nogai, Hendrik, Bender, Sebastian, Ellinghaus, Peter, Schuler, Martin H., Joerger, Markus, Cassier, Philippe, Penel, Nicolas, Cathomas, Richard, Richly, Heike, Schostak, Martin, Janitzky, Andreas, Wermke, Martin, Nogova, Lucia, Tai, David Wai-Meng, Sayehli, Cyrus, Gruellich, Carsten, Grande, Enrique, Navarro, Alejandra, Park, Se Hoon, Gillessen, Silke, Nogai, Hendrik, Bender, Sebastian, Ellinghaus, Peter, and Schuler, Martin H.

Published
2018

33. Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.

Author

Joerger, Markus, Cassier, Philippe Alexandre, Penel, Nicolas, Cathomas, Richard, Richly, Heike, Schostak, Martin, Janitzky, Andreas, Wermke, Martin, Nogova, Lucia, Tai, David Wai-Meng, Sayehli, Cyrus, Grullich, Carsten, Grande, Enrique, Navarro, Alejandro, Park, Se Hoon, Nogai, Hendrik, Bender, Sebastian, Ellinghaus, Peter, Schuler, Martin H., Joerger, Markus, Cassier, Philippe Alexandre, Penel, Nicolas, Cathomas, Richard, Richly, Heike, Schostak, Martin, Janitzky, Andreas, Wermke, Martin, Nogova, Lucia, Tai, David Wai-Meng, Sayehli, Cyrus, Grullich, Carsten, Grande, Enrique, Navarro, Alejandro, Park, Se Hoon, Nogai, Hendrik, Bender, Sebastian, Ellinghaus, Peter, and Schuler, Martin H.

Published
2018

35. STREAM: A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (S) treatment of chemonaïve patients (pts) with metastatic uveal melanoma (MUM).

Author

Scheulen, Max E., primary, Kaempgen, Eckhart, additional, Keilholz, Ulrich, additional, Heinzerling, Lucie, additional, Ochsenreither, Sebastian, additional, Abendroth, Annalena, additional, Hilger, Ralf A., additional, Grubert, Matthias, additional, Wetter, Axel, additional, Guberina, Nika, additional, Bauer, Sebastian, additional, Schuler, Gerold, additional, Bornfeld, Norbert, additional, Schuler, Martin H., additional, and Richly, Heike, additional

Published
2017
Full Text
View/download PDF

36. A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma

Author

Schelhorn, Juliane, Richly, Heike, Ruhlmann, Marcus, Lauenstein, Thomas C., and Theysohn, Jens Matthias

Subjects
radioembolization, Medizinische Fakultät » Universitätsklinikum Essen » Innere Klinik (Tumorforschung), Liver metastases, Medizinische Fakultät » Universitätsklinikum Essen » Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie, Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Nuklearmedizin, Medizin, ddc:61, Original Article, ddc:610, uveal melanoma
Abstract

Background:Overall survival (OS) of patients with hepatic metastases of uveal melanoma is strongly linked with hepatic tumor control. Due to the lack of an effective systemic chemotherapy, locoregional therapies like radioembolization should play an increasingly important role. Purpose: To report complications and response rates of radioembolization as salvage therapy for hepatic uveal melanoma metastases. Material and Methods: Between October 2006 and January 2014, eight patients (age, 59.1 ± 15.3 years; 5 men) with histologically proven uveal melanoma and hepatic metastases received radioembolization with glass microspheres at a single center. All patients had been heavily pretreated with multiple systemic/locoregional therapies resulting in a long median interval between diagnosis of hepatic metastases and radioembolization (17.1 months; range, 6.4-23.2 months). Follow-up consisted of clinical assessment, laboratory tests and tri-phasic computed tomography (CT) before and 1, 3, 6, 9, and 12 months after radioembolization. Response to therapy was evaluated by CT using RECIST version 1.1 and by survival time. Safety (laboratory and clinical toxicity) was rated according to Common Terminology Criteria for Adverse Events 4.03. Using Kaplan-Meier analysis time to progression of hepatic metastases (hTTP) and OS were calculated. Results: One month after radioembolization 50% of patients presented with stable and 50% with progressive disease. Median hTTP and OS after radioembolization were 4.3 weeks (range, 3.4-28.6 weeks) and 12.3 weeks (range, 3.7-62.6 weeks), respectively. Median OS after diagnosis of hepatic metastases was 19.9 months (range, 7.3-31.4 months). Radioembolization was tolerated well in all patients without toxicity higher than grade 2. Conclusion: Radioembolization is a safe salvage therapy even in heavily pretreated hepatic metastases of uveal melanoma.

Published
2015

37. WTZ-Tumorprofil-A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center : Two years experience

Author

Wiesweg, Marcel, Ting, Saskia, Reis, Henning, Worm, K., Kasper, Stefan, Bauer, Sebastian, Gauler, Thomas, Welt, Anja, Richly, Heike, Tewes, Mitra, Meiler, Johannes, Hense, Jörg, Eberhardt, Wilfried, Derks, Christian, Cortes-Incio, D., Skottky, S., Wohlschläger, Jeremias, Breitenbucher, F., Freitag, Lutz, Stamatis, Georgios, Schmid, Kurt Werner, and Schuler, Martin

Subjects
Medizin
Published
2014

43. Overcoming the proliferation rate paradox: Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205.

Author

Mross, Klaus B., primary, Scharr, Dirk, additional, Richly, Heike, additional, Bauer, Sebastian, additional, Krauss, Babett, additional, Krauss, Rolf, additional, Hauns, Bernhard, additional, Prenzel, Tanja, additional, Kohlhof, Hella, additional, Baumgartner, Roland, additional, and Scheulen, Max E., additional

Published
2015
Full Text
View/download PDF

48. Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

Author

Cruz Zambrano, Cristina, primary, Schuler, Martin H., additional, Machiels, Jean-Pascal H., additional, Hess, Dagmar, additional, Paz-Ares, Luis, additional, Awada, Ahmad, additional, von Moos, Roger, additional, Steeghs, Neeltje, additional, Rodon Ahnert, Jordi, additional, De Mesmaeker, Peggy, additional, Richly, Heike, additional, Herremans, Catherine, additional, Joerger, Markus, additional, Corral Jaime, Jesus, additional, Alsina, Maria, additional, Baffert, Fabienne, additional, Demanse, David, additional, Duval, Vincent, additional, Morozov, Alex, additional, and Dirix, Luc, additional

Published
2014
Full Text
View/download PDF

50. Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

Author

Rodon Ahnert, Jordi, primary, Schuler, Martin H., additional, Machiels, Jean-Pascal H., additional, Hess, Dagmar, additional, Paz-Ares, Luis, additional, Awada, Ahmad, additional, von Moos, Roger, additional, Steeghs, Neeltje, additional, Cruz Zambrano, Cristina, additional, De Mesmaeker, Peggy, additional, Richly, Heike, additional, Herremans, Catherine, additional, Joerger, Markus, additional, Corral Jaime, Jesus, additional, Alsina, Maria, additional, Baffert, Fabienne, additional, Demanse, David, additional, Duval, Vincent, additional, Morozov, Alex, additional, and Dirix, Luc, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results